Safety, tolerability and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese individuals with mild-to-moderate Alzheimer's disease: A phase IIa, multicenter, randomized, adjuvant and placebo clinical trial
暂无分享,去创建一个
E. Liu | R. Margolin | H. Arai | N. Ketter | N. Jackson | T. Yoshiyama | Y. Fujimoto | Yahong Peng | Kasia Lobello | Hideo Suzuki